
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CD117-shielded Cell
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Prime Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Prime Medicine will receive an exclusive option to license Cimeio’s cell shielding technology for CD117-shielded HSC transplant, as well as in vivo editing of CD117-shielded HSCs, for genetic diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : CD117-shielded Cell
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Prime Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
